Novavax (NVAX, Financials) shares jumped 17.1% to $7.32 as of 1:10 p.m. ET on Wednesday after the company said it received a request from the U.S. Food and Drug Administration for additional postmarketing clinical data related to its COVID-19 vaccine license application.
The company said the FDA issued a formal information request tied to its Biologics License Application (BLA) and asked for a postmarketing commitment. Novavax said it aims to respond promptly to move the vaccine closer to full regulatory approval.
The request comes after the April 1 Prescription Drug User Fee Act deadline, during which Novavax said it had constructive discussions with the agency.
Novavax stated that while it believes its application is approvable, final approval remains contingent on meeting the FDA's requirements.
The company cautioned that its forward-looking statementsincluding its expectations for approvalare subject to risks and uncertainties.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。